Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Arlington Capital Partners Announces the Acquisition of Micron Technologies

Published: Thursday, March 21, 2013
Last Updated: Thursday, March 21, 2013
Bookmark and Share
Arlington Capital Partners, a Washington announced the acquisition of Micron Technologies, Inc., in partnership with the company’s management team.

Headquartered in Malvern, PA, Micron is a leading global provider of particle size engineering and related analytical services to the pharmaceutical industry.

Micron focuses on solving the pharmaceutical industry’s most difficult bio-availability and drug delivery challenges through multiple particle size reduction technologies. The Company is the leading independent provider of micronization services for solubility enhancement of active pharmaceutical ingredients (“APIs”). Micron maintains state of the art facilities offering industry leading capabilities including distinctive containment technology for processing highly potent compounds. Micron’s personnel have unique expertise in jet milling, mechanical milling, containment processing and associated analytical services including material characterization testing and stability monitoring.

“Micron’s ability to provide leading bio-availability solutions across the drug development spectrum, from clinical phases to the commercial market, positions the Company as a trusted long-term partner with its pharmaceutical clients for their most demanding drug development needs,” said Matt Altman, a Partner at Arlington Capital Partners. “We are enthusiastic about building upon the Company’s leadership position and eager to continue to support the Company as it enhances and expands its global particle size engineering and analytical service offerings.”

Joseph Drost, CEO of Micron, commented, “We are extremely excited about our partnership with Arlington Capital. Arlington has a successful history of investing in healthcare and pharmaceutical services and shares our vision for growing Micron’s global capabilities and service offerings.

Arlington’s ability to provide significant strategic and capital support will further enable Micron to continue to expand our leading global position and better serve our worldwide pharmaceutical client base.”

David Wodlinger, a Principal at Arlington Capital said, “Micron is an ideal platform investment in a compelling growth industry and we look forward to working closely with the company’s management team to expand the business aggressively, both organically and through acquisition.”

Greenberg Traurig served as counsel to Arlington Capital Partners for the transaction. Fairmount Partners advised Micron on the transaction.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Monkeys Protected by Zika DNA Vaccine
Experimental Zika virus DNA vaccines successfully protected monkeys against Zika infection.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!